<DOC>
	<DOCNO>NCT03071770</DOCNO>
	<brief_summary>The purpose Phase I , single-dose , open-label trial evaluate pharmacokinetics safety ivosidenib ( AG-120 ) healthy , adult male Japanese Caucasian subject . The study plan evaluate 3 cohort single oral dose ivosidenib ( AG-120 ) Japanese Caucasian subject . Pharmacokinetic sample take place serially through-out duration subject participation .</brief_summary>
	<brief_title>Japanese Bridging Study Ivosidenib ( AG-120 ) Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Applicable Japanese Subjects Only : Japanese subject must bear Japan , parent grandparent Japanese origin , live outside Japan 5 year . Applicable Caucasian Subjects Only : NonJapanese subject must Caucasian ( ie , White ) may ethnicity . Healthy male subject 18 55 year age ( inclusive ) . Provision voluntary , write informed consent . Capable adhere trial restriction examination schedule , opinion Investigator . Must able communicate Investigator . Must good health determine Investigator accord past medical history , physical examination , vital sign , clinical laboratory test result , ECGs . Must body mass index ( BMI ) 18 29 kg/m2 ( inclusive ) , body weight 50120kg . Clinical laboratory test result ( serum chemistry , hematology , urinalysis ) must within normal limit consider Investigator clinically significant confirmation Agios Medical Monitor . Vital sign ( systolic diastolic blood pressure , pulse rate , oral body temperature ) assess supine position subject rest least 5 minute . Subject must afebrile vital sign within follow range screen , Day 1 pre dose : Systolic blood pressure : 90 140 mmHg ; Diastolic blood pressure : 50 90 mmHg ; Pulse rate : 40 110 bpm Must normal clinically acceptable 12lead ECG later Day 1 . Subjects must predose QT interval correct heart rate use Fridericia 's formula ( QTcF ) value average 3 value , â‰¤450 msec . An ECG may repeat determine subject eligibility confirmation Agios Medical Monitor . Subjects ( without vasectomy ) must agree abstain sexual intercourse agree use highly effective contraceptive method ( screen throughout course trial ) avoid father child course trial 90 day follow dose IMP . Subjects must refrain sperm donation entire duration trial 90 day follow dose AG 120 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject provide informed consent participate trial opinion Investigator . Any condition , include presence laboratory abnormality , place subject unacceptable risk participate trial . Recent history ( within 3 year prior dose ) clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematological , major disorder . Use prescribed systemic topical medication within 30 day 5 terminal halflives , whichever longer , IMP administration . Exposure investigational drug within 30 day prior IMP administration 5 half life investigational drug , know ( whichever longer ) . Use nonprescribed systemic topical medication ( include vitamin/mineral supplement , herbal medicine , eg , St. John 's Wort ) within 7 day IMP administration . Any surgical medical condition could affect drug absorption , distribution , metabolism , excretion ( eg , gastrectomy cholecystectomy ) Subjects plan elective medical procedure conduct trial ( eg , dental procedure ) . History clinically significant multiple drug allergy ( ie , 2 ) . Any clinically significant allergic disease . History drug abuse ( define current version Diagnostic Statistical Manual [ DSM ] ) within 2 year prior IMP administration , positive drug screen test due illicit drug time prior IMP administration screen period . History alcohol abuse within 2 year prior IMP administration , positive alcohol screen time prior IMP administration screen period . History smoke within 3 month prior IMP administration , positive urine cotinine screen time prior IMP administration screen period . Known human immunodeficiency virus ( HIV ) , hepatitis , know carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( HCV Ab ) , positive result screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Japanese</keyword>
	<keyword>Caucasian</keyword>
</DOC>